Colorectal adenocarcinoma

Researchers are testing whether regorafenib, a daily oral drug, works as well as standard combination chemotherapy for people with newly diagnosed metastatic colorectal cancer. The trial enrolls adults with good performance status who have not yet received treatment for metastati…

This study tested a special pump placed under the skin that sends chemotherapy directly to the liver through the hepatic artery. It was for people with colorectal cancer that had spread to the liver and who had already tried other chemotherapies. The goal was to see if this direc…

This trial is testing whether an experimental drug called JS015, when combined with standard chemotherapy or immunotherapy, is safe and effective for people with advanced solid tumors that have not responded to prior treatment. The study includes patients with certain cancers lik…

This early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…

This phase 3 trial tested whether combining sotorasib (a pill) and panitumumab (an infusion) can slow tumor growth better than standard chemotherapy in 160 adults with metastatic colorectal cancer that has a specific KRAS G12C mutation. Participants were randomly assigned to rece…

This pilot study tests whether a purified green tea extract called EGCG can help prevent colon cancer from coming back after surgery. 51 patients who had their colon cancer removed took either the extract or a placebo. Researchers are checking for changes in DNA methylation, a ma…

This study tests whether a combination of three drugs—cisplatin, nivolumab, and temozolomide—can shrink tumors in people with advanced colorectal cancer that has not responded to other treatments. The cancer must be a specific type called MMR-proficient. The trial involves 18 par…

This Phase 3 trial tested a new drug combination called MK-4280A (favezelimab plus pembrolizumab) against standard treatments (regorafenib or TAS-102) in 441 people with advanced colorectal cancer that had stopped responding to prior therapy. The goal was to see if the new combin…

This early-phase trial tested two drugs together—pembrolizumab (Keytruda) and XL888—in 47 people with advanced gastrointestinal cancers like colorectal and pancreatic cancer that had spread or could not be removed. The main goal was to find the safest dose and check for side effe…

This registry followed 152 patients with colorectal cancer that had spread mainly to the liver. Doctors used tiny beads called LifePearl Microspheres loaded with the chemotherapy drug irinotecan, delivered directly to the liver's blood supply. The goal was to see how and when thi…

This early-phase study tested a new drug, HBM1020, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The drug was given by IV every three weeks. Because this is a Phase 1 trial, i…

This early-phase study tested the safety of combining the immunotherapy drug pembrolizumab with precise, high-dose radiation (SBRT) to the liver in 15 adults with colorectal cancer that had spread only to the liver. The goal was to see if this combination could prevent the cancer…

This phase 2 study tested the immunotherapy drug prolgolimab in 30 people with a specific type of colorectal cancer (MSI/dMMR) that had not spread. Participants received the drug for 6 months before planned surgery. The main goal was to see if the cancer completely disappeared in…

This early-phase study tested a combination of two drugs, cabozantinib and TAS-102, in 15 people with advanced colorectal cancer that had spread and stopped responding to standard treatments. The main goal was to find the safest dose and identify side effects. The study is comple…

This phase 3 trial tested whether a surgical procedure called laparotomy plus heated chemotherapy (HIPEC) could improve outcomes for colorectal cancer patients at high risk of cancer spreading in the abdomen. 150 patients who had already undergone surgery and chemotherapy were ra…

This early-phase study tested a new drug called gevokizumab alongside standard cancer treatments in 167 adults with advanced colorectal, stomach, or kidney cancer that had spread. The goal was to find a safe and active dose and see if the combination could help control the diseas…

This early-stage study tested a new drug called cabotamig in 33 adults with advanced cancers of the digestive system (like colon, pancreas, or liver) that had stopped responding to standard treatments. The goal was to see if the drug is safe and how it affects the body and tumors…

This early-stage trial tested the safety and tolerability of a chemotherapy drug called raltitrexed when given as a heated solution directly into the abdomen (HIPEC) in 30 patients with colorectal cancer. The goal was to find the highest safe dose and understand how the drug beha…

This study tested a drug called romiplostim in 165 adults with gastrointestinal, pancreatic, or colorectal cancer who were receiving chemotherapy. The goal was to see if romiplostim could prevent low platelet counts (thrombocytopenia) that often force doctors to delay or reduce c…

This phase II trial tested a combination of three drugs—TAS-102, irinotecan, and bevacizumab—in 42 people with advanced colorectal cancer that had spread or couldn't be removed. The goal was to see if this mix could slow tumor growth better than standard treatments. Participants …

This study looked at whether taking daily aspirin and vitamin D, along with exercise and a low-fat diet, could help prevent colorectal cancer from returning in 16 patients who had no visible cancer but still had signs of cancer DNA in their blood. The goal was to see if these lif…

This study tested a combination of two drugs, lenvatinib and pembrolizumab, against the usual treatments for people with advanced colorectal cancer that had spread and stopped responding to prior therapy. About 563 adults took part. The goal was to see if the new combo helped peo…

This phase 1 trial tested a combination of regorafenib (a targeted therapy) plus two immunotherapy drugs (nivolumab and ipilimumab) in 39 patients with advanced colorectal cancer that had spread and stopped responding to chemotherapy. The goal was to find the safest dose and chec…

This Phase 3 study tested the drug FTD/TPI (a chemotherapy pill) against a placebo in 243 people who had surgery for colorectal cancer but still had cancer DNA in their blood. The goal was to see if the drug could prevent the cancer from coming back. Participants took the drug or…

This early-phase trial tested a combination of two drugs—pembrolizumab (an immunotherapy) and nintedanib (a drug that blocks blood vessel growth)—in 196 adults with advanced solid tumors that had worsened after standard treatment. The main goal was to find the safest dose of nint…

This phase 3 trial tests a new drug combination, MK-4280A (favezelimab plus pembrolizumab), against standard treatments (regorafenib or TAS-102) in 94 Chinese adults with advanced, PD-L1 positive colorectal cancer that has worsened after prior therapy. The main goal is to see if …

This study tested whether giving the immunotherapy drug pembrolizumab (Keytruda) along with chemotherapy before surgery can help shrink colorectal tumors and improve immune response. Thirty-three patients with non-metastatic colorectal cancer received the drugs, then had surgery.…

This study tested combinations of a new drug called etrumadenant (AB928) with other treatments in 227 people whose colorectal cancer had spread. The goal was to see if these combinations could shrink tumors or slow the cancer's growth. Participants received different drug mixes, …

This study tested whether adding the targeted drug panitumumab to standard chemotherapy (given through the liver artery and a vein) could help keep colorectal cancer from returning after liver metastases were surgically removed. It involved 75 adults with a specific gene type (wi…

This small, early-phase trial tested a combination of two drugs—cetuximab and capecitabine—as a maintenance treatment for people with a specific genetic type of advanced colorectal cancer (KRAS/BRAF wild-type). The main goals were to check safety, find the best dose, and see how …

Researchers at Jagiellonian University are studying whether a supplement made from freeze-dried black raspberries and strawberries affects inflammation in people over 65 receiving treatment for colorectal cancer. About 70 participants take the anthocyanin-rich supplement for 21 d…

This study tested whether an oral iron pill (ferric maltol) can improve anemia in 40 adults after colorectal cancer surgery, compared to standard care. The main goal was to see if a larger study is possible, while also checking blood iron levels. The approach is simple and aims t…

This study investigates whether a protein called WT1 is present in colorectal cancer tissue and whether its presence relates to tumor characteristics like grade, spread, and invasion. Researchers will analyze tissue samples from 60 patients with colorectal adenocarcinoma using a …

This study looked at whether an AI computer program could suggest cancer treatments that match what experts recommend. Researchers reviewed medical records of 30 people with stomach, colon, or pancreatic cancer. They entered key details into the AI and compared its suggestions to…

This study tested a new classification system for people whose colorectal cancer has spread only to the liver. Researchers looked at survival rates and compared different patient groups to see if the system helps predict outcomes. The goal is to better identify which patients mig…

This study looked at 74 people with metastatic colorectal cancer starting their first chemotherapy. Researchers took blood samples early in treatment to measure three markers: CEA, circulating tumor DNA, and total cell-free DNA. The goal was to see if early changes in these marke…

This study looked back at the medical records of 500 people with colorectal cancer from two regions in China. Researchers collected information on patients' backgrounds, lifestyle, and treatments to find patterns that affect survival. The goal was to understand regional differenc…

This study looks at whether the drug T-DXd works better than standard treatments for people with several types of HER2-positive solid tumors. Researchers will compare data from previous T-DXd trials with real-world medical records of patients who received standard care. The goal …

This completed study from West China Hospital examined tumor tissue from 100 colorectal cancer patients who had already received immunotherapy. Researchers measured levels of a protein called PHGDH to see if it was linked to how well the patients responded to treatment and how lo…

This study looked at 143 people in China who had a second surgery after rectal cancer treatment because of a leak or tumor return. Researchers wanted to find out what factors help the surgery succeed and whether patients can regain the ability to poop normally. The goal is to bet…

This study looked at 119 patients who had colon or rectal cancer surgery at a hospital in Damascus, Syria. The goal was to find out what raises the risk of a dangerous leak where the intestine is reconnected. Researchers then updated hospital guidelines to address those risks, es…

This study looked at whether two easy-to-use frailty checklists (FRAIL and FiND) can predict severe side effects from chemotherapy in adults aged 65 and older with gastrointestinal cancers. Researchers followed 84 patients who had already had surgery and were receiving standard c…

This study looked at 143 people in China who had repeat surgery after their first colorectal cancer operation failed or the cancer came back. The goal was to find out what helps the second surgery succeed and whether patients can regain normal bowel function. Researchers analyzed…